

18 March 2024

ASX Code: MXC

LSE Code: MXC

Results of Shareholder's General Meeting

A
S
X

R
E
L
E
A
S
E

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') would like to announce the results from the Company's General Meeting of Shareholders held today, Monday, 18 March 2024, in accordance with ASX Listing Rule 3.13.2.

The Company confirms that all motions put to the meeting were voted by poll, with all resolutions carried.

Details of the proxy voting and voting outcomes for all motions put to the meeting are set out in the attached report.

As a result of Resolution 1 having been passed at the meeting, shareholders have granted approval for the Company to change its name to **Argent Biopharma Ltd**, reflecting the final step in a comprehensive restructuring. The Company is currently in the process of notifying the Australian Securities and Investments Commission (**ASIC**) of the change of name and will update shareholders with additional details prior to the effective date.

—Ends—

Authorised for release by the board of directors, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@mgcpharma.co.uk

**UK IR/PR Advisers
IFC Advisory**

Graham Herring / Tim Metcalfe / Zach Cohen
+44 203 934 6630
mgcpharma@investor-focus.co.uk

MGC Pharmaceuticals Ltd

Rowan Harland
Company Secretary
+61 8 6555 2950
info@mgcpharma.co.uk

UK Brokers

Oberon Capital
Aimee McCusker / Adam Pollock
+44 203 179 5300
aimeemccusker@oberoninvestments.com
adampollock@oberoninvestments.com

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a prominent European pharmaceutical company with a strong commitment to creating accessible and ethically produced cutting-edge medicines. Our approach combines in-house research with innovative technologies, all aimed at discovering and producing treatments for currently unmet medical conditions.

The company's founders and executives are distinguished figures in the global pharmaceutical industry. Our central business strategy revolves around the development and supply of innovative medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia.

MGC Pharma maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products currently in the developmental stages. We've established strategic partnerships with renowned institutions and academia, fostering the optimization of our medicines' development. These medicines are produced in our EU-GMP Certified manufacturing facilities, ensuring the highest quality standards.

With a growing patient base in key regions like the USA, UK, Australia, and Ireland, MGC Pharma has also built a global distribution network through a wide-reaching group of commercial partners. This extensive network places us in a prime position to supply the global market effectively.

Follow us through our social media channels:

LinkedIn: MGC Pharmaceuticals Ltd.
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
Instagram: @mgc_pharma

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Change of Company name	Special	16,301,616 99.54%	54,468 0.33%	21,811 0.13%	10,040	16,323,435 99.67%	54,468 0.33%	10,040	Carried
2 Issue of Incentive Options to related party - Layton Mills	Ordinary	15,682,956 95.80%	662,718 4.05%	24,443 0.15%	17,818	15,707,407 95.95%	662,718 4.05%	17,818	Carried
3 Issue of Incentive Options to related party - Daniel Robinson	Ordinary	15,682,981 95.80%	662,793 4.05%	24,443 0.15%	17,718	15,707,432 95.95%	662,793 4.05%	17,718	Carried
4 Ratification of prior issue of Placement Securities	Ordinary	16,301,166 99.59%	42,321 0.26%	25,044 0.15%	19,404	16,326,218 99.74%	42,321 0.26%	19,404	Carried
5 Ratification of prior issue of Creditor Shares - Bright Global	Ordinary	15,689,900 95.86%	652,777 3.99%	24,443 0.15%	20,815	15,714,351 96.01%	652,777 3.99%	20,815	Carried
6 Ratification of prior issue of Creditor Shares - Elad Segev	Ordinary	15,689,120 95.83%	657,921 4.02%	24,443 0.15%	16,451	15,713,571 95.98%	657,921 4.02%	16,451	Carried
7 Ratification of prior issue of Creditor Shares - 2020 Ventures Pty Ltd	Ordinary	16,301,502 99.57%	45,985 0.28%	24,613 0.15%	7,918	16,326,123 99.72%	45,985 0.28%	7,918	Carried
8 Ratification of prior issue of Creditor Shares - Brett Mitchell	Ordinary	16,300,578 99.57%	46,190 0.28%	24,577 0.15%	16,590	16,325,163 99.72%	46,190 0.28%	16,590	Carried

9 Ratification of prior issue of Creditor Shares - Chieftain Securities (WA) Pty Ltd	Ordinary	16,298,764 99.55%	45,975 0.28%	27,267 0.17%	15,929	16,326,039 99.72%	45,975 0.28%	15,929	Carried
10 Ratification of prior issue of Creditor Shares - Nicole Godresse	Ordinary	15,689,756 95.84%	656,861 4.01%	24,629 0.15%	16,689	15,714,393 95.99%	656,861 4.01%	16,689	Carried
11 Ratification of prior issue of Creditor Shares - Turner Pope Investments	Ordinary	16,301,219 99.56%	45,089 0.28%	25,693 0.16%	15,934	16,326,920 99.72%	45,089 0.28%	15,934	Carried
12 Ratification of prior issue of Creditor Shares - Peterhouse Capital	Ordinary	16,301,469 99.57%	45,535 0.28%	24,977 0.15%	15,954	16,326,454 99.72%	45,535 0.28%	15,954	Carried
13 Ratification of prior issue of Creditor Shares - Australian Cannabis Ventures	Ordinary	16,304,130 99.57%	45,974 0.28%	24,443 0.15%	13,388	16,328,581 99.72%	45,974 0.28%	13,388	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.